Log in to save to my catalogue

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitox...

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitox...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_429cfaca4e8047249e5f275e8cfc363c

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

About this item

Full title

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Publisher

London: BioMed Central Ltd

Journal title

Current controlled trials in cardiovascular medicine, 2023-09, Vol.24 (1), p.591-591, Article 591

Language

English

Formats

Publication information

Publisher

London: BioMed Central Ltd

More information

Scope and Contents

Contents

Background About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen). However, CR rates remain low, with les...

Alternative Titles

Full title

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_429cfaca4e8047249e5f275e8cfc363c

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_429cfaca4e8047249e5f275e8cfc363c

Other Identifiers

ISSN

1745-6215

E-ISSN

1745-6215

DOI

10.1186/s13063-023-07421-x

How to access this item